Mareque M, Climente M, Martinez-Moragon E, Padilla A, Oyagüez I, Touron C, Torres C, Martinez A
Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain
J Asthma. 2023;60(6):1210-1220
Mareque M, Climente M, Martínez E, Padilla A, Oyagüez I, Touron C, Torres C
Cost-effectiveness of benralizumab in patients with uncontrolled severe eosinophilic asthma in Spain
European Respiratoy Society International Congress. Barcelona. 04-06 sep 2022
Capel M, Mareque M, Álvarez CJ, Oyagüez I
Cost-effectiveness of fixed-dose combinations therapies for chronic obstructive pulmonary disease treatment
Clin Drug Investig (2018) 38:611-620
Capel M, Mareque M, Alvarez C, Lindner L, Oyagüez I
Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain
European Respiratory Society International Congress (ERS). Milan, Italy. 9 – 13 sep 2017
Echave M, Ojanguren ME, Elías I, De Andrés-Nogales F, Oyagüez I, Casado MÁ, Crespo C
Cost-effectiveness of tiotropium in the treatment of patients with asthma
18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015
Rodríguez-González Moro JM, Menendez R, Campins M, Lwoff N, Oyagüez I, Echave M, Rejas J, Antoñanzas F
Cost-effectiveness of a 13-valent conjugate pneumococcal vaccination program in COPD patients aged 50+ years in Spain
18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015
Jiménez-Ruiz CA, Solano-Reina S, Signes-Costa J, de Higes-Martinez E, Granda-Orive JI, Lorza-Blasco JJ, Riesco-Miranda JA, Altet-Gomez N, Barrueco-Ferrero M, Oyagüez I, Rejas J
Budgetary Impact Analysis on Funding Smoking-cessation Drugs in Patients with Chronic Obstructive Pulmonary Disease in Spain
Int J Chron Obstruct Pulmon Dis. 2015;10:2027-36
Solé A, Poveda JL, Girón R, Prados C, De Gracia J, Casado MA
Economic Impact linked to the reduction of exacerbations when a treatment regime with inhaled antibiotics is switched to aztreonam lysine in patients with cystic fibrosis and chronic pulmonary infection caused by Pseudomonas aeruginosa
17th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Amsterdam, Holland. 8-12 nov 2014
Torres C, Betoret I, Sabater E, Riera M, Casado MA, Figueras M